Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in a late-stage lung cancer trial conducted by its partner Akeso (AKESF) in ...
FiercePharma

Akeso, Summit’s ivonescimab tops Keytruda in lung cancer survival, with strong data in PD-L1-high patients

As a trailblazer, ivonescimab now offers reassurance to all PD-1xVEGF developers after demonstrating a head-to-head overall survival advantage over Keytruda, Akeso CEO Michelle Xia, Ph.D., said.
Health Chosun

[Healthcare Industry Roundup] Korea MSD Launches 'Keytruda Subcutaneous Injection' in South Korea

Korea MSD Launches 'Keytruda Subcutaneous Injection' in South Korea Korea MSD has launched 'Keytruda Subcutaneous Injection,' a subcutaneous formulation of the anti-PD-1 immuno ...
Yahoo Finance

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...
Yahoo

Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

Merck & Co.'s cancer immunotherapy Keytruda is one of the pharmaceutical industry's biggest successes. The drug's arrival in 2014 introduced a new way of treating cancer and, over time, it became ...